AGIO Agios Pharmaceuticals Inc
Price (delayed)
$35.22
Market cap
$2.02B
P/E Ratio
2.97
Dividend/share
N/A
EPS
$11.86
Enterprise value
$2B
Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In
Highlights
The revenue has grown by 36% year-on-year and by 11% since the previous quarter
Agios Pharmaceuticals's gross profit has increased by 35% YoY and by 10% QoQ
Agios Pharmaceuticals's equity has surged by 90% YoY but it has decreased by 5% QoQ
The quick ratio is up by 31% since the previous quarter but it is down by 3.6% year-on-year
Key stats
What are the main financial stats of AGIO
Market
Valuations
Earnings
Shares outstanding
57.3M
Market cap
$2.02B
Enterprise value
$2B
Price to earnings (P/E)
2.97
Price to book (P/B)
1.3
Price to sales (P/S)
54.82
EV/EBIT
2.78
EV/EBITDA
2.72
EV/Sales
54.76
Revenue
$36.5M
Gross profit
$32.33M
Operating income
$463.4M
Net income
$673.73M
EBIT
$717.97M
EBITDA
$735.15M
Free cash flow
-$391.49M
Per share
Balance sheet
Liquidity
EPS
$11.86
EPS diluted
$11.64
Free cash flow per share
-$6.89
Book value per share
$27.02
Revenue per share
$0.64
TBVPS
$29.28
Total assets
$1.66B
Total liabilities
$122.24M
Debt
$56.99M
Equity
$1.54B
Working capital
$884.44M
Debt to equity
0.04
Current ratio
11.9
Quick ratio
11.06
Net debt/EBITDA
-0.03
Margins
Efficiency
Dividend
EBITDA margin
2,014.2%
Gross margin
88.6%
Net margin
1,845.9%
Operating margin
1,269.7%
Return on assets
53.1%
Return on equity
58.9%
Return on invested capital
64.1%
Return on capital employed
45.4%
Return on sales
1,967.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AGIO stock price
How has the Agios Pharmaceuticals stock price performed over time
Intraday
4.36%
1 week
6.02%
1 month
5.99%
1 year
31.42%
YTD
7.18%
QTD
7.18%
Financial performance
How have Agios Pharmaceuticals's revenue and profit performed over time
Revenue
$36.5M
Gross profit
$32.33M
Operating income
$463.4M
Net income
$673.73M
Gross margin
88.6%
Net margin
1,845.9%
The operating margin has surged by 187% year-on-year but it has declined by 13% since the previous quarter
The revenue has grown by 36% year-on-year and by 11% since the previous quarter
Agios Pharmaceuticals's gross profit has increased by 35% YoY and by 10% QoQ
The net margin has declined by 10% since the previous quarter
Growth
What is Agios Pharmaceuticals's growth rate over time
Valuation
What is Agios Pharmaceuticals stock price valuation
P/E
2.97
P/B
1.3
P/S
54.82
EV/EBIT
2.78
EV/EBITDA
2.72
EV/Sales
54.76
Agios Pharmaceuticals's equity has surged by 90% YoY but it has decreased by 5% QoQ
The P/B is 48% below the 5-year quarterly average of 2.5 and 41% below the last 4 quarters average of 2.2
The revenue has grown by 36% year-on-year and by 11% since the previous quarter
AGIO's P/S is 16% below its last 4 quarters average of 65.6
Efficiency
How efficient is Agios Pharmaceuticals business performance
The company's return on invested capital fell by 17% QoQ
AGIO's return on equity is down by 16% since the previous quarter
The ROA has contracted by 14% from the previous quarter
Agios Pharmaceuticals's return on sales has decreased by 11% QoQ
Dividends
What is AGIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AGIO.
Financial health
How did Agios Pharmaceuticals financials performed over time
The total assets has surged by 77% year-on-year but it has declined by 7% since the previous quarter
AGIO's current ratio is up by 32% since the previous quarter but it is down by 3% year-on-year
The debt is 96% smaller than the equity
Agios Pharmaceuticals's equity has surged by 90% YoY but it has decreased by 5% QoQ
The debt to equity has shrunk by 56% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.